How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,974 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Guidelines on Supraventricular Tachycardia (for the management of patients with)

Paediatric and Congenital Cardiology (AEPC) Josep Brugada Chairperson Spain Corresponding authors: Josep Brugada, Cardiology Department, Hospital Clinic, and Pediatric Arrhythmia Unit, Hospital Sant Joan de Déu, University of Barcelona, Spain. Tel: +34 3460 902 2351, Fax: +34 3493 227 1777, Email: jbrugada@clinic.cat. Search for other works by this author on: , Demosthenes G Katritsis Chairperson Greece Demosthenes G. Katritsis, Department of Cardiology, Hygeia Hospital, E. Stavrou 4, 15123 Athens (...) of supraventricular tachycardia 9 Table 6 Differential diagnosis of narrow and wide QRS tachycardias 9 Table 7 Initial evaluation of the patient with supraventricular tachycardia 10 Table 8 Possible responses of narrow QRS tachycardia to vagal manoeuvres and adenosine 13 Table 9 Summary of key electrocardiographic criteria that suggest ventricular tachycardia rather than supraventricular tachycardia in wide complex tachycardia 14 Table 10 Causes of physiological sinus tachycardia 19 Table 11 Average success

Full Text available with Trip Pro

2019 European Society of Cardiology

182. Supporting Rapid Learning and Improvement Across Ontario’s Health System

review examined attempts to adopt the rapid-learning health-system paradigm, with an emphasis on implementation and evaluating the impact on current medical practices, and found minimal focus on evaluating impacts on healthcare delivery and patient outcomes. What implementation considerations need to be kept in mind • While many barriers to implementing these elements may exist at the level of patients, providers, organizations and systems, perhaps the biggest barrier lies in achieving agreement (...) of patient decision aids) c) the organizations that deliver care (e.g., patient-experience surveys; co-design of programs and services; membership of quality-improvement committees and advisory councils) d) the organizations that oversee the professionals and other organizations in the system (e.g., professional regulatory bodies; quality-improvement bodies; ombudsman; and complaint processes) e) policymaking (e.g., committees making decisions about which services and drugs are covered; government

2019 McMaster Health Forum

183. Diagnosis and Management of Acute Pulmonary Embolism

Plasminogen Activator for Occluded Coronary Arteries HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly HERDOO2 Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L; Obesity with body mass index ≥30 kg/m 2 ; or Older age, ≥65 years H-FABP Heart-type fatty acid-binding protein HIV Human immunodeficiency virus HR Hazard ratio INR International (...) Pulmonary embolism PEA Pulmonary endarterectomy PEITHO Pulmonary Embolism Thrombolysis trial PERC Pulmonary Embolism Rule-out Criteria PERT Pulmonary Embolism Response Team PESI Pulmonary Embolism Severity Index P-gp P-glycoprotein PH Pulmonary hypertension PIOPED Prospective Investigation On Pulmonary Embolism Diagnosis PISAPED Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis PREPIC Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption PVR Pulmonary vascular

Full Text available with Trip Pro

2019 European Society of Cardiology

184. Management of Dyslipidaemias

by this author on: , Manuela Casula Italy Search for other works by this author on: , Lina Badimon Spain Search for other works by this author on: , M John Chapman France Search for other works by this author on: , Guy G De Backer Belgium Search for other works by this author on: , Victoria Delgado Netherlands Search for other works by this author on: , Brian A Ference United Kingdom Search for other works by this author on: , Ian M Graham Ireland Search for other works by this author on: , Alison Halliday (...) , Meral Kayikcioglu, Philippe Moulin, Xavier Pintó, Kausik K. Ray, Željko Reiner, Erik Stroes, Alexandros D. Tselepis, Margus Viigimaa and Michal Vrablik: representing the EAS. European Heart Journal , ehz455, Published: 31 August 2019 Citation François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen

Full Text available with Trip Pro

2019 European Society of Cardiology

185. Organizational Guideline for the Delivery of Stereotactic Radiosurgery for Brain Metastasis in Ontario

Organizational Guideline for the Delivery of Stereotactic Radiosurgery for Brain Metastasis in Ontario Guideline 21-4 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Organizational Guideline for the Delivery of Stereotactic Radiosurgery for Brain Metastasis in Ontario A. Sahgal, S. Kellett, M. Ruschin, J. Greenspoon, M. Follwell, J. Sinclair, J. Perry, O. Islam and the Stereotactic Radiosurgery for Brain Metastasis Guideline Development Group Report (...) Date: August 27, 2019 For information about this document, please contact Arjun Sahgal the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Sahgal A, Kellett

2019 Cancer Care Ontario

186. Regional Models of Care for Systemic Treatment: Standards for the Organization and Delivery of Systemic Treatment

For information about this document, please contact Dr. Leta Forbes, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit the CCO website at http: https://www.cancercareontario.ca/en/guidelines-advice or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Forbes L (...) for CPOE and labelling.* For additional information, please see Computerized Prescriber Order Entry (CPOE) in the Outpatient Oncology Setting, Patient Safety Issues: Key Components of Chemotherapy Labelling, Systemic Treatment Computerized Prescriber Order Entry (ST CPOE: Best Practice Guideline for Intravenous and Oral Chemotherapy and Appendix 1 #3-5 . ? Ability to submit e-claims eligibility forms.* ? Potential for videoconference, remote web-based teaching as part of multidisciplinary cancer

2019 Cancer Care Ontario

187. Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2018

metastases. FDG PET/CT upstaged 24.6% of patients and downstaged 4.9% of patients as well as modified 37.7% of treatment plans [2]. Furthermore, the sensitivity (83.2% versus 69.8%, p 18 F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: A meta-analysis. Onco Targets Ther. 2018 20 Jun;11:3597-608. 36. Garcia Vicente AM, Talavera Rubio MP, Dominguez Ferreras E, Calle Primo C, Amo-Salas M, Tello Galan MJ, et al. (18)F-FDG PET/contrast enhanced CT in the standard follow-up of patients (...) , brief summary of the identified evidence, and not a detailed evaluation of its quality and relevance. 2 METHODS Literature Search Strategy Full-text articles published between July and December 2018 were systematically searched through MEDLINE and EMBASE for evidence from primary studies and systematic reviews. The search strategies used are available upon request to the PEBC. Inclusion Criteria for Clinical Practice Guidelines Any clinical practice guidelines that contained recommendations

2019 Cancer Care Ontario

188. Systemic Therapy for Advanced or Recurrent Endometrial Cancer and Advanced or Recurrent Uterine Papillary Serous Carcinoma

://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Gawlik C, Carey M, Faught W, Fung Kee Fung M, Chambers A; Members of the Gynecology Cancer Disease Site Group. Systemic therapy for advanced or recurrent endometrial cancer, and advanced or recurrent uterine papillary serous carcinoma. Covens A, Durocher-Allen L, reviewers. Toronto (ON): Cancer Care Ontario; 2004 Aug 17 [Endorsed 2019 Jul 23 (...) M, Stanmir G, Langleben G, Letendre E, Gagne G. Paclitaxel and cisplatin: an active regimen in metastatic cancer of the endometrium. Int J Gynecol Cancer 1999;9 (suppl 1):69. 34. Santoro A, Maiorino L, Santoro M, Forestieri V, Forestieri P. Carboplatin and vinorelbine combination for treatment of advanced endometrial carcinoma [abstract]. Proc Am Soc Clin Oncol 1998;17:375a. 35. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, et al. Cisplatin-, epirubicin- and paclitaxel

2019 Cancer Care Ontario

189. Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection

, the lead author, through the PEBC at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Meyers B, Cosby R, Quereshy F, Jonker D. Adjuvant systemic chemotherapy for stage II and III colon cancer (...) application or use in any way. Contact Information For information about this document, please contact Dr. Brandon Meyers, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca Section 3: Guideline Methods

2019 Cancer Care Ontario

190. Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum

about this document, please contact A. Finelli, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Finelli A, Coakley N, Chin J, Flood T, Loblaw A, Morash C (...) instruments and the tumour o Laparoscopic RNU must take place in a closed system. o Avoid morcellation of the tumour and use an endobag for tumour extraction o The kidney and ureter must be removed en bloc with the bladder cuff o Invasive or large (T3/T4 and/or N+/M+) tumours are contraindications for laparoscopic RNU until proven otherwise. ? Laparoscopic RNU is safe in experienced hands when adhering to strict oncologic principles. There is a tendency toward equivalent oncological outcomes after

2019 Cancer Care Ontario

191. Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

. Models of care for cancer survivorship [Internet]. Toronto: Cancer Care Ontario; 2017 March [cited 2018 Jan 3]. Available at: https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/246 3 Sussman J, McBride M, Sisler J, Kim G, Game L, Ozokwelu E, et al. Assessment of re-entry support mechanisms during survivorship care transitions. Poster session presented at: Health Quality Transformation Presents: Quality Matters 2016; 2016 Oct 20; Toronto. 4 Mittmann N, Beglaryan H, Liu N, Seung SJ (...) , Rahman F, Gilbert J, et al. Evaluating the impact of survivorship models on health system resources and costs. J Clin Onc. 2018 Mar;36(7_suppl):1-1. DOI: 10.1200/JCO.2018.36.7_suppl.1 5 Brouwers MC, Vukmirovic M, Tomasone JR, Grunfeld E, Urquhart R, O’Brien M, et al. Documenting coordination of cancer care between primary care providers and oncology specialists in Canada. Can Fam Physician. 2016 Oct;62(10):e616-e625. 6 Trebble TM, Hansi N, Hydes T, Smith MA, Baker M. Process mapping the patient

2019 Cancer Care Ontario

192. Position statement on the hormonal management of adult transgender and gender diverse individuals

disease to map the way we live and die. WHO: Geneva, 2018. (viewed June 2018). Telfer MM, Tollit MA, Pace CC, Pang KC. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. Med J Aust 2018; 209: 132–136. Delahunt JW, Denison HJ, Sim DA, et al. Increasing rates of people identifying as transgender presenting to Endocrine Services in the Wellington region. N Z Med J 2018; 131: 33–42. Coleman E, Bockting W, Botzer M, et al. Standards of care (...) for the health of transsexual, transgender, and gender‐nonconforming people, version 7. Int J Transgenderism 2012; 13: 165–232. Hembree WC, Cohen‐Kettenis PT, Gooren L, et al. Endocrine treatment of gender‐dysphoric/gender‐incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017; 102: 3869–3903. Bretherton I, Thrower E, Grossmann M, et al. Cross‐sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare

2019 MJA Clinical Guidelines

193. Shared decision making training programs for doctors: A Rapid Review

the use of shared decision making by healthcare professionals. Cochrane Database of Systematic Reviews, (7). 2. Epstein, R. M., Duberstein, P. R., Fenton, J. J., Fiscella, K., Hoerger, M., Tancredi, D. J,& Kaesberg, P. (2017). Effect of a patient-centered communication intervention on oncologist-patient communication, quality of life, and health care utilization in advanced cancer: the VOICE randomized clinical trial. JAMA Oncology, 3(1), 92-100. 3. Gist, D. L., Bhushan, R., Hamarstrom, E., Sluka, P (...) Methodology The following methods were used when undertaking a search, inclusion and selection of evidence for this report. Inclusion/Exclusion Criteria Table 1. Inclusion/Exclusion criteria Population Include: Doctors in hospitals Exclude: General practitioners, nurses, other health professionals Interventions Include: Training and/or education in shared decision making (SDM) Context Include: In the hospital setting Exclude: General Practice Outcomes Any Types of evidence Include: All types (Peer

2019 Monash Health Evidence Reviews

194. Reducing costs in hospitals

was required to follow standard process improvement (PI) methodology – IMPROVE: (I)dentify, (M)easure, (P)roblem analysis, (R)emedy, (O)perationalise, (V)alidate and (E)valuate, and have a projected, validated financial benefit. Although facilitators from the Performance Improvement (PI) department were available for support, it was the leader’s responsibility to ensure the project progressed. Leaders (i.e., process owners) were required to report to senior leadership on a monthly basis in a formal, fact (...) 2019). The searches were sorted according to relevance. Results A total of 1020 articles were screened by one reviewer (GY) according to the Inclusion/Exclusion criteria in Table1. Articles that did not report on primary outcomes of interest were excluded. A total of eight articles were selected for their inclusion in the review. Conclusions This report assembles lessons about transformation efforts they have been undertaken to address the pressures from rising health care costs while providing

2019 Monash Health Evidence Reviews

195. Trust in Health Professionals

as essential to building a trusting relationship. This review did not identify any determinants, tools or interventions specific to the paediatric population. The information provided in this review has been taken from primary and secondary health services as well as inpatient and outpatient settings.Trust in Health Professionals 7 References 1. Allinson M and Chaar B, How to build and maintain trust with patients. The Pharmaceutical Journal, 2016. 297(7895). 2. Muller E, et al., Assessment of Trust (...) Trust in Health Professionals Trust in Health Professionals 1 Trust in Health Professionals Citation Garrubba M & Yap G. 2019. Trust in Health Professionals. Centre for Clinical Effectiveness, Monash Health, Melbourne, Australia. Executive Summary Background Trust in health professionals is important because health and healthcare in general involves an element of uncertainty and risk for the vulnerable patient who is reliant on the competences and intentions of their clinicians [1]. Patient

2019 Monash Health Evidence Reviews

196. IV night teams: Impact on Infection rates, insertion success and deskilling

catheters in adults: a systematic review and meta- analysis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):908-18. 25. Golombek SG, Rohan AJ, Parvez B, et al. Proactive" management of percutaneously inserted central catheters results in decreased incidence of infection in the ELBW population. J Perinatol. 2002 Apr- May;22(3):209-13. 26. Brown, P. (1984). An IV specialty team can mean savings for hospital and patient. NITA, 7, 387-388. 27. McDiarmid S, Scrivens N, Carrier M, Sabri E, Toye B, Huebsch L (...) Rickard and Dr Peter Carr were consulted about your questions and they indicated that they were not aware of any research on the effectiveness of IV night teams. Scientific and grey literature databases were searched to find both synthesised and primary evidence on IV night teams, infection rates and deskilling. Articles were screened and selected according to the inclusion/exclusion criteria in Table A1 (appendix). Only articles published in English were considered. A summary of findings are included

2019 Monash Health Evidence Reviews

197. Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer Guideline 1-14 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer A. Arnaout, N. Varela, M. Allarakhia, L. Grimard, A. Hey, J. Lau, L. Thain, A. Eisen, and the Staging in Early Stage Breast Cancer Advisory Committee 1 Report Date: October 7, 2019 (...) For information about this document, please contact Dr. Angel Arnaout, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca 1 A full list of participants is provided in Appendix 1. PEBC Report Citation

2019 Cancer Care Ontario

198. Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen

. Eribulin is already recommended after 2 previous chemotherapy treatments, and there are no trials which compare its effectiveness given after 1 or 2 previous treatments, so this remains uncertain. Eribulin meets NICE's criteria to be considered a life-extending treatment at the end of life. The estimates of cost effectiveness for eribulin range from £36,200 to £82,700 per quality-adjusted life year (QAL Y) gained. The most plausible estimate of cost effectiveness, based on a revised company model (...) for these treatments' . Recommended Recommended dose and dose and schedule schedule 1.23 mg/m 2 is administered intravenously over 2 to 5 minutes on days 1 and 8 of every 21-day cycle. Price Price £361.00 per 0.88 mg/2 ml solution for injection vial and £541.50 per 1.32 mg/ 3 ml solution for injection vial (excluding VAT; British national formulary [BNF] online, accessed October 2017). The company has agreed a patient access scheme with the Department of Health. If eribulin had been recommended, this scheme would

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

199. Public health service provision by community pharmacies: a systematic map of evidence

: This report should be cited as: Stokes G, Rees R, Khatwa M, Stansfield C, Burchett H, Dickson, K, Brunton G, Thomas J (2019) Public health service provision by community pharmacies: a systematic map of evidence. London: EPPI-Centre, Social Science Research Unit, Institute of Education, University College London. Funding This report is independent research commissioned by the National Institute for Health Research (NIHR) Policy Research Programme (PRP) for the Department of Health and Social Care (DHSC (...) Type of review 179 15.2 User involvement/Advisory Group 179 15.3 Inclusion/exclusion criteria 180 15.4 Literature search 180 15.5 Screening of studies 182 15.6 Coding 183 15.7 Producing a systematic map of evidence 183 15.8 Flow of studies through the review 184 Appendices 187 Public health service provision by community pharmacies: a systematic map of evidence iv Appendix 1: PRISMA checklist 187 Appendix 2: Table of linked studies (n=47) 189 Appendix 3: List of resources searched and MEDLINE

2019 EPPI Centre

200. Risk Factors for Endometrial Cancer - A review of the evidence

and criteria for grading carcinogenicity 88 Glossaries 92 Abbreviations 97 References 100 Endometrial cancer risk factors: A review of the evidence iv Figures Figure 1 Age–specific incidence of uterine cancer in Australia, by age group, 2015 17 Figure 2 Age–specific incidence of uterine cancer in Australia over time, 1982–2014, and different age groups 18 Endometrial cancer risk factors: A review of the evidence v Tables Table 1 Differences between type I and type II endometrial cancer 7 Table C.1 (...) International Agency for Research on Cancer (2015): Categories of evidence of carcinogenicity 88 Table C.2 World Cancer Research Fund/American Institute for Cancer Research (2018): Criteria for grading evidence for cancer prevention 90 Endometrial cancer risk factors: a review of the evidence 6 Introduction 1 1.1 Context There are two major types of uterine cancer: endometrial cancer and uterine sarcoma. Endometrial cancers arise in the lining of the uterus whereas uterine sarcomas develop in the muscle

2019 Cancer Australia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>